All In Biotech

NDA 210331 · Alimera Sciences INC

Yutiq

Fluocinolone Acetonide · Intravitreal · Corticosteroid

Discontinued

Last checked: Nov 20, 2026Latest source record: Oct 12, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Oct 12, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

63

20 Phase 3, 7 recruiting

FAERS reports

2,444

757 serious, 42 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 19, 2026.

1. INDICATIONS AND USAGE YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ contains a corticosteroid and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. ( 1 )

Mechanism: Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A 2 via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 12, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LetterReview
1 products under this application
  • YUTIQ · FLUOCINOLONE ACETONIDE 0.18MG · IMPLANT, INTRAVITREAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluocinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use519
  • product dose omission issue199
  • drug ineffective187
  • pruritus166
  • rash143
  • no adverse event130
  • diarrhoea115
  • psoriasis95
  • headache90
  • fatigue89
  • pain85
  • nausea81

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
200514
20067
200711
20089
200915
201017
201128
201232
201317
201426
201553
201675
201766
201873
2019115
2020163
2021174
2022286
2023190
2024585
2025295
2026185

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Yutiq (Fluocinolone Acetonide) · HCPCS J7314

2024 spending

$13.7M

Beneficiaries

1,218

1,386 claims

Per beneficiary

$11,238

2024 ASP limit $527.80 per unit

View as table
YearSpending
2020$4,541,901
2021$6,285,301
2022$9,370,225
2023$11,403,309
2024$13,688,154

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 139 on PubMed

Sponsor: Alimera Sciences INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.